Orexo on the verge of launching new drug in the USA

Swedish pharmaceutical development company Orexo provides improved treatments using proprietary drug delivery technology. Orexo is currently focusing on the US market with two launched products available in the USA and a third product with expected approval in July 2013.

Orexo relies on reformulation technologies and especially sublingual formulations. The company develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining already known substances with patented proprietary technologies.

Current portfolio
The current portfolio of EU and US comprises approved products that are marketed under license. In addition, Orexo has built up successful collaboration projects with several international pharmaceutical development companies. Launched and licensed products include Abstral® and Edluar™.
Abstral is a pharmaceutical that provides rapid relief of breakthrough pain in cancer patients. Orexo has the product rights to Abstral in the USA. In Europe and the rest of the world the rights have been transferred to the ProStrakan Group. Edluar is a pharmaceutical for the treatment of short-term insomnia and Meda has a global license for this product.

Close to approval
A key component of the company strategy is to develop new pharmaceuticals combining well-documented substances and drug delivery technologies that Orexo has invented, developed or acquired. The objective is to develop drugs with unique features, such as fast onset of action and predictable effects.
Orexo now has a number of ongoing development programs for new pharmaceuticals. At present the focus is on Zubsolv, a pharmaceutical to be used for the treatment of opioid dependence. CFO Carl-Johan Blomberg: “We expect an approval from the US FDA in early July this year. Most of our current effort is dedicated to realizing our project and successfully launching Zubsolv. In parallel we are implementing the advantum suite that we expect to run live in a few months”.

A system well-tailored to Orexo’s needs
Orexo has recently invested in the interactive advantum document and business management system especially tailored to the life science industry, the advantum Life Sciences Suite. “As advantum has the ability to adapt and grow as we subsequently develop our company and our product portfolio, we feel that it is a system well-tailored to our needs both now and in the future”, concludes Catrin Molund, Director IT & Office Management at Orexo.
The advantum Life Sciences Suite is part of a comprehensive product portfolio marketed by InfoTech Scandinavia, a Microsoft Certified Partner.


Swedish Life Science SNL 2013-2 - Affärstidningen Näringsliv

Näringsliv 2013-2

Huvudtema: Swedish Life Science
Huge interest for Swedish Life Science around the world

That the image of Sweden abroad is positive is nothing new, and currently we are seeing a significant renewed interest for what is happening within Swedish life science. At least, this is what Ola Björkman, CEO of Stockholm-Uppsala Life Science believes.

Back to top